Suchergebnisse - "*Antirheumatic Agents"

PubPharm (30.208)

31

Janus kinase inhibitors and tumour necrosis factor inhibitors show a favourable safety profile and similar persistence in rheumatoid arthritis, psoriatic arthritis and spondyloarthritis : real-world data from the BIOBADASER registry

enthalten in: Annals of the rheumatic diseases | 2024

von Hernández-Cruz, B. | Otero-Varela, L. | Freire-González, M. | +11

32

Long-term clinical and radiological effectiveness and safety of ultralow doses of rituximab in rheumatoid arthritis : observational extension of the REDO trial

enthalten in: RMD open | 2024

von den Broeder, N. | Verhoef, L. | de Man, Y. | +7

33

Enhancing lupus outcomes by means of biology beyond overt clinical features, exemplified in an in-depth investigation of the effects of circadian rhythm disruption

enthalten in: Lupus science & medicine | 2024

von Parodis, I.

34

OpenSAFELY : The impact of COVID-19 on azathioprine, leflunomide and methotrexate monitoring, and factors associated with change in monitoring rate

enthalten in: British journal of clinical pharmacology | 2024

von Brown, A. | Fisher, L. | Curtis, H. | +25

35

Effects of tapering conventional synthetic disease-modifying antirheumatic drugs to drug-free remission versus stable treatment in rheumatoid arthritis (ARCTIC REWIND) : 3-year results from an open-label, randomised controlled, non-inferiority trial

enthalten in: The Lancet. Rheumatology | 2024

von Kjørholt, K. | Sundlisæter, N. | Aga, A. | +19

36

Non-thyroidal disease syndrome in patients with systemic lupus erythematosus : relation to disease inflammatory activity

enthalten in: Clinical rheumatology | 2024

von Meng, X. | Lv, A. | Tang, M. | +9

37

Letter to the Editor : "Development and validation of equations for conversion from DAS28ESR and DAS28CRP to the SDAI in patients with rheumatoid arthritis"

enthalten in: Clinical rheumatology | 2024

von Yu, T. | Qian, S. | Li, M.

CommentOn: Clin Rheumatol. 2022 Dec;41(12):3697-3706. - PMID 35945466

38

Tapering conventional synthetic DMARDs towards sustained drug-free remission in rheumatoid arthritis

enthalten in: The Lancet. Rheumatology | 2024

von van Mulligen, E.

39

Impact of DMARD treatment and systemic inflammation on all-cause mortality in patients with rheumatoid arthritis and interstitial lung disease : a cohort study from the German RABBIT register

enthalten in: RMD open | 2024

von Rudi, T. | Zietemann, V. | Meissner, Y. | +6

40

A validation of register-derived diagnoses of interstitial lung disease in patients with inflammatory arthritis : data from the NOR-DMARD study

enthalten in: Scandinavian journal of rheumatology | 2024

von Provan, S. | Ahlfors, F. | Bakland, G. | +6